Funcionalidad, implementación y líneas de desarrollo de la plataforma educativa SWAD / OpenSWAD

La plataforma de b-learning y gestión académica SWAD ofrece múltiples herramientas de apoyo a la gestión docente y al aprendizaje, y ha sido utilizada durante 19 años por 180.000 usuarios en la Universidad de Granada (UGR) y en los últimos 4 años por otros 23.000 usuarios procedentes de 1.500 instituciones educativas de todo el mundo. Este artículo resume las funcionalidades actuales de la plataforma y su implementación, y propone la incorporación de una serie de técnicas como son la gamificación, la geolocalización y la minería de datos con los objetivos de mejorar la motivación y el rendimiento académico de los estudiantes y de facilitar al profesorado las tareas de evaluación.The b-learning and academic management platform SWAD offers multiple tools to support teaching management and learning, and has been used for 19 years by 180,000 users at the University of Granada (UGR) and in the last 4 years by other 23,000 users from 1,500 educational institutions around the world. This article summarizes the current functionalities of the platform and its implementation, and proposes the incorporation of a series of techniques such as gamification, geolocation and data mining with the goals of improving students' motivation and academic performance, and supporting teachers in assessment tasks.Universidad de Granada: Departamento de Arquitectura y Tecnología de Computadore

Tobacco and cognitive performance in schizophrenia patients: the design of the COGNICO study

Las personas con esquizofrenia constituyen una parte sustancial de las personas que todavía fuman. La hipótesis de la automedicación en relación al rendimiento cognitivo mantiene que los pacientes fuman para mejorar su déficit cognitivo basándose en los efectos estimulantes de la nicotina. El objetivo de este artículo es describir la metodología del estudio COGNICO. Estudio cuasiexperimental, observacional, prospectivo, multicéntrico y con seguimiento a 3, 6, 12 y 18 meses. Fue llevado a cabo en tres ciudades del norte de España (Oviedo, Ourense y Santiago de Compostela). Se reclutaron 81pacientes con esquizofrenia fumadores (edad media de 43,35 años (DT=8,83). 72,8% varones). Se asignaron a 3 grupos: a) control: pacientes fumadores; b) pacientes que dejan de fumar mediante parches de nicotina; c)pacientes que dejan de fumar mediante vareniclina. Como medida primaria se aplicó la batería neuropsicológica MATRICS. Además, se llevó a cabo una evaluación comprehensiva de los pacientes, que incluía el número de cigarrillos por día, la dependencia física y psicológica a la nicotina y el CO expirado. También se realizó una evaluación clínica general (PANSS, HDRS, ICG, C-SSRS) así como un seguimiento de las medidas antropométricas y los signos vitales. Se pretende identificar la relación entre el patrón de consumo de tabaco y el rendimiento cognitivo mediante la comparación de las puntuaciones en la batería neuropsicológica MATRICS durante los períodos de seguimiento.People with schizophrenia constitute a substantial part of the people who still smoke. Regarding cognitive performance, the self-medication hypothesis states that patients smoke to improve their cognitive deficits based on the stimulating effects of nicotine. The aim of this paper is to describe in detail the methodology used in the COGNICO study. A quasi-experimental, observational, prospective, multicenter study with follow-ups over 18 months was conducted in three cities in northern Spain (Oviedo, Ourense and Santiago de Compostela). A total of 81 outpatient smokers with schizophrenia were recruited with a mean age 43.35 years (SD = 8.83), 72.8% of them male. They were assigned to 3 groups: a) control group (smokers); b) patients who quit smoking using nicotine patches; c) patients who quit smoking with Varenicline. The MATRICS neuropsychological battery was applied as a primary measure. In addition, a comprehensive assessment of patients was performed, including the number of cigarettes per day, physical and psychological dependence on nicotine and CO expired. Clinical evaluation (PANSS, HDRS, CGI, C-SSRS), anthropometric measurements and vital signs assessment was also performed. The aim is to identify the relationship between the pattern of tobacco use and cognitive performance by comparing scores on the neuropsychological battery MATRICS during the follow-up periods (3, 6, 12 and 18months). The importance of this study lies in addressing a topical issue often ignored by clinicians: the unacceptably high rates of tobacco use in patients with severe mental disorder

Roadmap on metasurfaces

ABSTRACT: Metasurfaces are thin two-dimensional metamaterial layers that allow or inhibit the propagation of electromagnetic waves in desired directions. For example, metasurfaces have been demonstrated to produce unusual scattering properties of incident plane waves or to guide and modulate surface waves to obtain desired radiation properties. These properties have been employed, for example, to create innovative wireless receivers and transmitters. In addition, metasurfaces have recently been proposed to confine electromagnetic waves, thereby avoiding undesired leakage of energy and increasing the overall efficiency of electromagnetic instruments and devices. The main advantages of metasurfaces with respect to the existing conventional technology include their low cost, low level of absorption in comparison with bulky metamaterials, and easy integration due to their thin profile. Due to these advantages, they are promising candidates for real-world solutions to overcome the challenges posed by the next generation of transmitters and receivers of future high-rate communication systems that require highly precise and efficient antennas, sensors, active components, filters, and integrated technologies. This Roadmap is aimed at binding together the experiences of prominent researchers in the field of metasurfaces, from which explanations for the physics behind the extraordinary properties of these structures shall be provided from viewpoints of diverse theoretical backgrounds. Other goals of this endeavour are to underline the advantages and limitations of metasurfaces, as well as to lay out guidelines for their use in present and future electromagnetic devices. This Roadmap is divided into five sections: 1. Metasurface based antennas. In the last few years, metasurfaces have shown possibilities for advanced manipulations of electromagnetic waves, opening new frontiers in the design of antennas. In this section, the authors explain how metasurfaces can be employed to tailor the radiation properties of antennas, their remarkable advantages in comparison with conventional antennas, and the future challenges to be solved. 2. Optical metasurfaces. Although many of the present demonstrators operate in the microwave regime, due either to the reduced cost of manufacturing and testing or to satisfy the interest of the communications or aerospace industries, part of the potential use of metasurfaces is found in the optical regime. In this section, the authors summarize the classical applications and explain new possibilities for optical metasurfaces, such as the generation of superoscillatory fields and energy harvesters. 3. Reconfigurable and active metasurfaces. Dynamic metasurfaces are promising new platforms for 5G communications, remote sensing and radar applications. By the insertion of active elements, metasurfaces can break the fundamental limitations of passive and static systems. In this section, we have contributions that describe the challenges and potential uses of active components in metasurfaces, including new studies on non-Foster, parity-time symmetric, and non-reciprocal metasurfaces. 4. Metasurfaces with higher symmetries. Recent studies have demonstrated that the properties of metasurfaces are influenced by the symmetries of their constituent elements. Therefore, by controlling the properties of these constitutive elements and their arrangement, one can control the way in which the waves interact with the metasurface. In this section, the authors analyze the possibilities of combining more than one layer of metasurface, creating a higher symmetry, increasing the operational bandwidth of flat lenses, or producing cost-effective electromagnetic bandgaps. 5. Numerical and analytical modelling of metasurfaces. In most occasions, metasurfaces are electrically large objects, which cannot be simulated with conventional software. Modelling tools that allow the engineering of the metasurface properties to get the desired response are essential in the design of practical electromagnetic devices. This section includes the recent advances and future challenges in three groups of techniques that are broadly used to analyze and synthesize metasurfaces: circuit models, analytical solutions and computational methods

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Psychometric properties of a Spanish-version of the Schizophrenia Objective Functioning Instrument (Sp-SOFI)

El Instrumento de Funcionamiento Objetivo para la Esquizofrenia (SOFI) es unaentrevista para evaluar el nivel de funcionamiento comunitario en relación con el da˜no cognitivoy los síntomas psicopatológicos. El objetivo del estudio consistió en examinar las propiedadespsicométricas de la versión espa˜nola de la SOFI (Sp-SOFI) en una muestra de 155 pacientesambulatorios con esquizofrenia. Los índices de discriminación de la Sp-SOFI oscilaron entre0,21 y 0,77. El análisis factorial exploratorio mostró una estructura esencialmente unidimensional.El alfa de Cronbach fue 0,93. El coeficiente de fiabilidad test-retest fue 0,87 (p < 0,001).La correlación canónica entre la Sp-SOFI y la Escala de Funcionamiento Personal y Social (PSP)fue 0,83. El coeficiente de correlación múltiple entre la Sp-SOFI y la Escala de Evaluación dela Actividad Global (EEAG) fue 0,44. Las puntuaciones en la Sp-SOFI fueron significativamentediferentes entre los pacientes con puntuaciones altas y bajas en la Escala del Síndrome Positivoy Negativo (PANSS) (p < 0,001). La Sp-SOFI discriminó entre pacientes con trastorno deesquizofrenia dudoso, leve, moderado y grave de acuerdo con la Escala de Impresión ClínicaGlobal de Esquizofrenia (CGI-SCH) (p < 0,001). La Sp-SOFI es un instrumento fiable y válido parala práctica clínica

Roadmap on metasurfaces

Metasurfaces are thin two-dimensional metamaterial layers that allow or inhibit the propagation of electromagnetic waves in desired directions. For example, metasurfaces have been demonstrated to produce unusual scattering properties of incident plane waves or to guide and modulate surface waves to obtain desired radiation properties. These properties have been employed, for example, to create innovative wireless receivers and transmitters. In addition, metasurfaces have recently been proposed to confine electromagnetic waves, thereby avoiding undesired leakage of energy and increasing the overall efficiency of electromagnetic instruments and devices. The main advantages of metasurfaces with respect to the existing conventional technology include their low cost, low level of absorption in comparison with bulky metamaterials, and easy integration due to their thin profile. Due to these advantages, they are promising candidates for real-world solutions to overcome the challenges posed by the next generation of transmitters and receivers of future high-rate communication systems that require highly precise and efficient antennas, sensors, active components, filters, and integrated technologies. This Roadmap is aimed at binding together the experiences of prominent researchers in the field of metasurfaces, from which explanations for the physics behind the extraordinary properties of these structures shall be provided from viewpoints of diverse theoretical backgrounds. Other goals of this endeavour are to underline the advantages and limitations of metasurfaces, as well as to lay out guidelines for their use in present and future electromagnetic devices. This Roadmap is divided into five sections: 1. Metasurface based antennas. In the last few years, metasurfaces have shown possibilities for advanced manipulations of electromagnetic waves, opening new frontiers in the design of antennas. In this section, the authors explain how metasurfaces can be employed to tailor the radiation properties of antennas, their remarkable advantages in comparison with conventional antennas, and the future challenges to be solved. 2. Optical metasurfaces. Although many of the present demonstrators operate in the microwave regime, due either to the reduced cost of manufacturing and testing or to satisfy the interest of the communications or aerospace industries, part of the potential use of metasurfaces is found in the optical regime. In this section, the authors summarize the classical applications and explain new possibilities for optical metasurfaces, such as the generation of superoscillatory fields and energy harvesters. 3. Reconfigurable and active metasurfaces. Dynamic metasurfaces are promising new platforms for 5G communications, remote sensing and radar applications. By the insertion of active elements, metasurfaces can break the fundamental limitations of passive and static systems. In this section, we have contributions that describe the challenges and potential uses of active components in metasurfaces, including new studies on non-Foster, parity-time symmetric, and non-reciprocal metasurfaces. 4. Metasurfaces with higher symmetries. Recent studies have demonstrated that the properties of metasurfaces are influenced by the symmetries of their constituent elements. Therefore, by controlling the properties of these constitutive elements and their arrangement, one can control the way in which the waves interact with the metasurface. In this section, the authors analyze the possibilities of combining more than one layer of metasurface, creating a higher symmetry, increasing the operational bandwidth of flat lenses, or producing cost-effective electromagnetic bandgaps. 5. Numerical and analytical modelling of metasurfaces. In most occasions, metasurfaces are electrically large objects, which cannot be simulated with conventional software. Modelling tools that allow the engineering of the metasurface properties to get the desired response are essential in the design of practical electromagnetic devices. This section includes the recent advances and future challenges in three groups of techniques that are broadly used to analyze and synthesize metasurfaces: circuit models, analytical solutions and computational methods.</p

“En los bordes del archivo: escrituras periféricas, escrituras efímeras en los Virreinatos de Indias”

En los bordes del archivo es el sitio web de "En los bordes del archivo: escrituras periféricas, escrituras efímeras en los Virreinatos de Indias”, proyecto coordinado entre dos equipos de investigación de la Universidad Complutense de Madrid (UCM) y del Consejo Superior de Investigaciones Científicas (CSIC).© En los bordes del archivo - 2017. Algunos derechos reservados. Licencia Creative Commons.. Consulta realizada en 2019-03-22.La finalidad que orienta el Proyecto Coordinado “En los bordes del archivo: escrituras periféricas, escrituras efímeras en los Virreinatos de Indias” queda definida en la voz que encabeza su título, estudiada en relación con la escritura hispanoamericana colonial y abordada desde una comprensión amplia del término, no sólo en su sentido más positivista, en tanto acumulación o repositorio de documentos para la conformación de la verdad historiográfica y la imposición del poder imperial, sino en las acepciones paralelas de “lugar de la memoria” y de “metáfora epistémica”, de herramienta que permite la interpretación “arqueológica” de los saberes.Peer reviewe

Promoción turística sostenible de la reserva de la biosfera Tajo-Tejo Internacional

Convocatoria proyectos de innovación de Extremadura 2020/2021Se describe un proyecto llevado acabo por varios centros educativos ubicados en la zona de la Reserva de la Biosfera Tajo-Tejo Internacional (RBTTI) que pretendía contribuir a la transformación sostenible del entorno mediante su conocimiento y promoción, implementando las competencias digital, social y ciudadana y la cultura emprendedora mediante metodologías activas como el aprendizaje servicio. Entre los objetivos principales del proyecto destacan: dar a conocer las implicaciones de la RBTTI; diseñar una campaña de promoción de la RBTTI mediante trípticos y vídeos promocionales; conocer la Reserva a través de las principales vías pecuarias y caminos que comunican los pueblos; descubrir los principales elementos socioculturales, históricos y tradicionales de la Reserva; valorar la importancia del territorio para conservar la biodiversidad: paisajes, ecosistemas, fauna y flora representativa; relacionar la trashumancia y las vías pecuarias como rasgos identificativos de la Reserva, vinculándolo con la historia y rasgos culturales de los pueblos y valorar el emprendimiento y la iniciativa personal, el asosiacionismo y creación de redes de cooperación en y entre pueblos como motor de desarrolloExtremaduraES

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk